National Health Insurance Administration news the national supplies belt procurement began.

Pharmaceutical Network September 14th, September 11th, the official website of the State Health Insurance Administration announced that on September 10th, a symposium on centralized belt procurement of pharmaceuticals and high-value medical supplies was held to study the deployment of drugs and high-value medical supplies centralized belt procurement work.
the meeting showed that the centralized volume procurement reform has achieved remarkable results, we must unswervingly push this work to further.
to speed up the expansion of the scope of collection, efforts to crack the medical supplies standards are not the same, classification is not clear and other issues, do a solid job of heart stent concentration with volume procurement work.
also called for strengthening the quality supervision of the whole life cycle of selected products, implementing "zero tolerance" for quality problems, and investigating and prosecuting them in accordance with the law.
to be in accordance with the provisions of the procurement and use of selected drugs, consumables, to prevent the emergence of recruitment without picking, mining and not using.
Qilu Pharmaceuticals, Lepu Medical Related Persons, experts from the Chinese Academy of Medical Sciences, Peking University First Hospital, Beijing Friendship Hospital affiliated with Capital Medical University, and relevant officials from the medical insurance departments of Tianjin and Anhui made presentations.
According to Seber Blue Equipment previously reported that on July 3, the State Health Insurance Administration issued the "National Organization Crown Bracket Centralized Band Purchase Program (Draft for Comments)" shows that the public medical institutions will be the main body to carry out the crown vein stent centralized belt procurement, has launched its own coronary stent belt volume procurement or no qualified medical institutions in the provinces except.
of the crown vein stent product, which is the target of the centralized belt purchase, shall be approved by the drug regulatory department to obtain a valid medical device registration certificate material.
is made of cobalt chromium alloy and platinum chromium alloy, the drug carrier is loaded with repamycin or derivatives, the drug carrier coating properties of non-Teflon coronary stent.
The above-mentioned draft for comments shows that in this volume procurement, in 2019 more than 1000 public medical institutions, military medical institutions should participate, other public medical institutions, military medical institutions, medical insurance fixed-point social-run medical institutions in accordance with the arrangements of the provinces to participate voluntarily.
Domestic bracket four giants understand that China's crown bracket field has basically completed domestic replacement, including major foreign-funded enterprises including Medtron, Boston Science, Abbott, less than 30% of the domestic market share, domestic major enterprises including minimally invasive, Lepu, Jiwei, Sano Medical, etc., the total market share of domestic manufacturers has exceeded 70%.
meters of intranet data show that minimally invasane medical and Lepu medical market share of more than 20%, Jiwei medical city accounted for about 15%, Sano medical market accounted for about 10%, enterprise-related market layout and product information as follows.
Healthcare's annual report shows that the micro-invasional cardiovascular business generated revenue of $265 million (about RMB1.8 billion) in 2019, up 35.5 percent from the previous year and accounting for 33.4 percent of total revenue.
's revenue from minimally invascopic medical drug equip stents increased 32.8% from 2018, with four drug equip stents and four balloon products on sale, including the FirehawkTM coronary repamycin targeted equip stent system .? FirehawkTM?) revenue increased 51.6% year-on-year, and Firebird 2TM coronary repamycin equiped cobalt-based alloy stent system (?? Firebird2TM?) revenue increased 22.9% year-on-year.
addition to the rapid growth of the domestic market and market recognition of the Firehawk bracket and the cost-effective Firebird bracket, the winning bid also boosted sales.
2019, Lepu Medical Stent System achieved operating income of 1.79 billion yuan, up 26.71 percent year-on-year, according to the company's annual report.
Among them, crown support products achieved operating income of 1.53 billion yuan, up 23.34% YoY, and supporting auxiliary supplies (ball bag catheters, conducts, etc.) achieved operating income of 260 million yuan, up 50.95 percent YoY.
reporting period, the proportion of the non-carrier drug stent system (Nano) in the metal stent sales structure was 46.05%.
bioabsorbent stents (NeoVas) are selling well, with case implants completed in hundreds of hospitals in 29 provinces across the country, contributing to new performance growth, accounting for 10.24 per cent of crown stent sales structures.
's core innovation is the bio-absorbable stent NeoVas stent system, which was officially approved for registration by NMPA in February 2019, ushering in a new era of "interventional implant-free" technology.
Medical, a subsidiary of Parkson International, acquired a 93.37 percent stake in Parkson International Group for 5,895 million yuan in 2018.
annual report of Lanfan Medical showed that during the reporting period, its cardiac intervention devices achieved operating income of 1.74 billion yuan, accounting for 49.99 percent of the company's total business revenue.
Blue Sail Medical's Parsons International is the world's fourth largest heart stent research and development, production and sales enterprises, ranked second only to Abbott, Boston Science and Medtron, crown stent market share in the world's fourth, China's top three.
All kinds of stent products produced by Pershing International are sold to more than 90 countries and regions around the world, including BioFreedomTM, BioMatrixTM, Axel ® (EXCEL), EXCROSSAL and other flagship products, including drug-coated stents (DCS), drug wash-out stents (DES), bare metal stents and balloons and balloon catheters and other cardiac intervention surgery-related devices.
Among them, biodegradable coating drug empellation stent Exel ® (EXCEL) has a market share of 20% in the multi-year segment, making it one of the top three heart stent brands in China, with a cumulative sales volume of more than 2.2 million by the end of 2019 since its launch.
according to its annual report, Sano Medical's main products are coronary drug stents and balloon catheters, with revenue of about 440 million yuan in 2019, up 14.5% YoY, and net profit of about 87 million yuan, down 0.07% YoY.
's main product, BuMA Biodegradable Drug Coating Coronary Stent System, was approved for sale in December 2010 and its current market share has increased from 8.99% in 2015 to 11.62% in 2017.
said its next-generation BuMA Supreme stent products, as well as products such as the "thin-walled" magnesium alloy full-degradation bracket, will guarantee the company's continued profitability.
.